Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction | Zendy

Friedrich Mittermayer | Zendy; Georg Schaller | Zendy; Johannes Pleiner | Zendy; Katarzyna Krzyżanowska | Zendy; Stylianos Kapiotis | Zendy; Michael Roden | Zendy; Michael Wolzt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction

Author(s) -

Friedrich Mittermayer,

Georg Schaller,

Johannes Pleiner,

Katarzyna Krzyżanowska,

Stylianos Kapiotis,

Michael Roden,

Michael Wolzt

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-2130

Subject(s) - rosiglitazone , medicine , endocrinology , vasodilation , insulin resistance , endothelium , endothelial dysfunction , triglyceride , insulin , cholesterol

Free fatty acids (FFAs) cause insulin resistance and vascular endothelial dysfunction. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone acts as insulin sensitizer and could exert vasoprotective properties by preservation of endothelium-dependent vasodilation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research